Pomaglumetad methionil
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Dec 1, 2011 → Oct 1, 2012
NCT ID
NCT01487083About Pomaglumetad methionil
Pomaglumetad methionil is a phase 3 stage product being developed by Eli Lilly for Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01487083. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01487083 | Phase 3 | Terminated |
Competing Products
20 competing products in Schizophrenia